Replies to post #80194 on Avid Bioservices Inc (CDMO)

[geocappy1]

Another app might be discoverered/decided when all the data from all the trials are crunched. Example: no cancers cured, but everyone noted a halt in the progression of their macular degeneration, arthritis, impotence, or depression.

I have seen a a halt and even a drop in the progression of my financial situation. Seriously, all this could be true, however, I think the emphasis on NSCLC is directed to the potential to see a financial return. If the NSLCL data is bad, most shareholders will have a insurmountable climb back to see any money. That is except for ATONE, because he will have millions of shares and always at the lowest prices.

[sunstar]

Entdoc, thanks for your, always, informative observations. I agree, there is a large body of Peregrine trial data now coming to maturity and this should be very powerful and persuasive.

Bavi has been showing great safety and efficacy in the trial results we have seen, and are now seeing in the new data from the second-line lung cancer (NSCLC) trial. You have also previously written about the potential of attaching enhancing elements to bavituximab: (arming) the basic bavi mAb. I would be interested in anything you can say about the possible variety of armed mAbs that might be employed when you have the time.

sunstar